Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Filings indexed 848 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings
2026-05-14 English
FORM 8-K
Regulatory Filings
2026-05-14 English
8-K - Ocugen, Inc. (0001372299) (Filer)
Regulatory Filings
2026-05-05 English
8-K - Ocugen, Inc. (0001372299) (Filer)
Regulatory Filings
2026-05-04 English
ARS - Ocugen, Inc. (0001372299) (Filer)
Annual Report
2026-04-28 English
SCHEDULE 13G/A - Ocugen, Inc. (0001372299) (Subject)
Major Shareholding Notification
2026-03-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.